Evidence map›Paper›PMID 33062193›Full record

ArticleOncotarget2020

Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy.

Wojciech Dawicki, Kevin J H Allen, Ravendra Garg, Eileen M Geoghegan, Mark S Berger, Dale L Ludwig, Ekaterina Dadachova

Abstract read
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wojciech DawickiCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Kevin J H AllenCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Ravendra GargCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.
Eileen M GeogheganActinium Pharmaceuticals, New York, NY, USA.
Mark S BergerActinium Pharmaceuticals, New York, NY, USA.
Dale L LudwigActinium Pharmaceuticals, New York, NY, USA.
Ekaterina DadachovaCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapies, and adoptive cell therapy (ACT) in general, represent one of the most promising anti-cancer strategies. Conditioning has been shown to improve the immune homeostatic environment to enable successful ACT or CAR-T engraftment and expansion

Indexed as

131Iodine177Lutetiumadoptive cell therapyanti-CD45 targeted lymphodepletionradioimmunotherapy

Identifiers

PMID33062193
PMCPMC7533072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.